Claims for Patent: 11,517,573

Summary for Patent: 11,517,573

Title:	Therapeutic compositions, combinations, and methods of use
Abstract:	This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.
Inventor(s):	Udai BANERJI
Assignee:	Institute of Cancer Research
Application Number:	US17/470,471
Patent Claims:	1. A method of treating ovarian cancer or non-small cell lung cancer in a subject in need thereof, the method comprising orally administering to the subject an effective amount of CH5126766, or a pharmaceutically acceptable salt thereof, in combination with an effective amount of defactinib, or a pharmaceutically acceptable salt thereof, wherein CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, are administered as a cycle comprising administering CH5126766, or a pharmaceutically acceptable salt thereof, twice a week and defactinib, or a pharmaceutically acceptable salt thereof, twice daily for three weeks and then not administering CH5126766, or a pharmaceutically acceptable salt thereof, and defactinib, or a pharmaceutically acceptable salt thereof, for one week. 2. The method of claim 1, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 0.5 mg to 10 mg per administration. 3. The method of claim 2, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 3.2 mg per administration. 4. The method of claim 2, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is administered at a dose of 4 mg per administration. 5. The method of claim 1, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 100 mg to 500 mg per administration. 6. The method of claim 5, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 200 mg per administration. 7. The method of claim 5, wherein defactinib, or a pharmaceutically acceptable salt thereof, is administered at a dose of 400 mg per administration. 8. The method of claim 1, wherein the cancer is characterized as having a mutation in EGFR, FGFR, ALK, ROS1, PI3K, NF-1, BRAF, HRAS, KRAS or NRAS. 9. The method of claim 1, wherein the cancer is characterized as having a mutation in RAS, BRAF, or NF-1. 10. The method of claim 9, wherein the mutation in RAS is a mutation in HRAS, KRAS, or NRAS. 11. The method of claim 1, wherein the ovarian cancer is low grade serous ovarian cancer. 12. The method of claim 1, wherein CH5126766, or a pharmaceutically acceptable salt thereof, is a potassium salt of CH5126766.